Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome

NCT07710196 is registered in ClinicalTrials.gov with Nacuity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07710196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07710196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis PigmentosaAssociated With Usher Syndrome
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
October 31, 2026
Completion date
April 30, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa (rp), usher syndrome